Merck KGaA, Darmstadt, Germany and Bio-Techne Corp., a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. On vacation and dreaming of retirement? Use our Social Security ...

The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said. Merck KGaA has agreed to buy Bio-Techne for $11.3 billion ...

Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life ...

Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.

Merck KGaA agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the ...

Germany's Merck KGaA is poised to increase the size of its life sciences business, which provides tools for research, drug discovery, and manufacturing, with an $11.3 billion deal to acquire US rival ...

Bio-Techne is a market leader in proteins, immunoassays, clinical diagnostic controls, and other reagents that are crucial for the academic, biopharmaceutical, and diagnostic markets. On June 25, 2026 ...

German pharmaceutical company Merck KGaA to purchase Bio-Techne in $11.3 billion transaction Acquisition price set at $73 per share, representing a 24% premium over Wednesday’s close Bio-Techne shares ...

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...